Biologics and biosimilars differ in which respect?

• A. Biosimilars are exact copies of biologics
• B. Biologics are simple small molecules, biosimilars are complex
• C. Biologics are still experimental, biosimilars are approved for use
• D. Biologics are complex drugs made from living organisms, while biosimilars are highly similar but not identical to biologics

Answer: (D)

Biologics are large, complex molecules produced by living cells, with properties shaped by the production process and post‑translational modifications. Because they come from living systems, every batch can vary slightly, and exact replication is effectively impossible.

Biosimilars are not exact copies. They are designed to be highly similar to a reference biologic, with no clinically meaningful differences in safety, purity, or potency. To demonstrate similarity, they undergo thorough analytical comparisons, preclinical studies, and clinical trials. Small differences in manufacturing can change factors like folding, glycosylation, or charge variants, which is why exact identity isn’t achievable and why the term “highly similar” is used rather than “identical.”

That’s why the correct understanding is that biologics are complex drugs made from living organisms, while biosimilars are highly similar but not identical to the original biologic. The other statements misrepresent the nature of biologics or biosimilars—biologics aren’t simple small molecules, and biologics aren’t still only experimental.